Onyx Pharmaceuticals and Bayer HealthCare Pharmaceuticals reported today that Nexavar failed a Phase III trial to treat a form of melanoma. Nexavar (R) is a drug developed by partners Onyx and Bayer to treat cancer. The multicenter, randomized, double-blind, placebo-controlled trial was stopped early after the drug failed to prolong life in patients, the primary endpoint. The patients enrolled in the trial had stage III or stage IV melanoma that could not be surgically removed. They were randomized to receive 400 mg tablets of Nexavar twice a day or placebo. The patients also received two chemotherapeutic agents. A planned interim analysis by the independent Data Monitoring Committee (DMC) reviewed the data and concluded that overall survival rate among patients receiving Nexavar was not improved. Although the DMC discontinued the study they did note that there were no serious side effects reported.